AzurRx launches OPTION 2 cystic fibrosis trial in Europe

MS1819 will be given in enteric capsules for gastric protection and optimal delivery of enzyme to the duodenum. Credit: Mahmoud Ahmed from Pixabay.



  • Option 2 trial